Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH08-08-0556
Issue:2009: 101/5 (May) pp. 795-990
Pages:860-866

Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects

Thales R. Cipriani1; Ana Helena P. Gracher1; Lauro M. de Souza1; Roberto J. C. Fonseca2; Celso L. R. Belmiro2; Philip A. J. Gorin1; Guilherme L. Sassaki1; Marcello Iacomini1
1Laboratório de Química de Carboidratos, Departamento de Bioquímica e Biologia Molecular, Universidade Federal do Paraná, Curitiba, Paraná, Brazil; 2Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho, Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Summary

Evaluated were the anticoagulant and antithrombotic activities, and bleeding effect of two chemically sulfated polysaccharides, obtained from citric pectin, with different average molar masses. Both low-molecular-weight (Pec-LWS, 3,600 g/mol) and highmolecular- weight sulfated pectins (Pec-HWS, 12,000 g/mol) had essentially the same structure, consisting of a (1→4)-linked α-D-GalpA chain with almost all its HO-2 and HO-3 groups substituted by sulfate. Both polysaccharides had anticoagulant activity in vitro, although Pec-HWS was a more potent antithrombotic agent in vivo, giving rise to total inhibition of venous thrombosis at a dose of 3.5 mg/kg body weight. Surprisingly, in contrast with heparin, Pec-HWS and Pec-LWS are able to directly inhibit α-thrombin and factor Xa by a mechanism independent of antithrombin (AT) and/or heparin co-factor II (HCII). Moreover, Pec-HWS provided a lower risk of bleeding than heparin at a dose of 100% effectiveness against venous thrombosis, indicating it to be a promising antithrombotic agent.

Keywords

anticoagulant, Antithrombotic, Sulfated polysaccharide, citrus pectin

DOI

http://dx.doi.org/10.1160/TH08-08-0556

You may also be interested in...

1.

Roberto J. C. Fonseca1, Stephan-Nicollas M. C. G. Oliveira1, Fábio R. Melo1, Maria G. Pereira2, Norma M. B. Benevides2, Paulo A. S. Mourão1

Thrombosis and Haemostasis 2008 99 3: 539-545

http://dx.doi.org/10.1160/TH07-10-0603

2.

Fábio R. Melo, Paulo A. S. Mourão

Thrombosis and Haemostasis 2008 99 3: 531-538

http://dx.doi.org/10.1160/TH07-10-0649

3.

Wolfgang Wienen1, Jean-Marie Stassen2, Henning Priepke1, Uwe Joerg Ries1, Norbert Hauel1

Thrombosis and Haemostasis 2007 98 2: 333-338

http://dx.doi.org/10.1160/TH07-02-0113



Articles

You've 225 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...